This case provides real-world evidence supporting the efficacy and tolerability of trastuzumab deruxtecan (DS-8201) as a salvage therapy in an elderly patient with HR+/HER2-low advanced breast cancer, demonstrating favorable tumor response and manageable adverse effects. This evidence concerns the gene ERBB2 and neoplasm.